Immunological and hematological effects of IL-5(Rα)-targeted therapy: An overview.
Marwan HassaniLeo KoendermanPublished in: Allergy (2018)
IL-5 is an important cytokine for priming and survival of mature eosinophils and for proliferation and maturation of their progenitors. Hence, IL-5(Rα) targeting will be increasingly used in diseases where eosinophils are the key immune effector cells such as eosinophilic asthma (EA), hypereosinophilic syndrome (HES), eosinophilic esophagitis (EE), and eosinophilic granulomatosis with polyangiitis (EGPA). Therefore, several neutralizing monoclonal antibodies directed against IL-5 (mepolizumab and reslizumab) and its receptor IL-5Rα (benralizumab) have found or will find their way to the clinic. While the clinical effect of these drugs has been extensively investigated and reviewed, the understanding of the underlying immunological and hematological mechanisms remains less clear. This review will discuss the translational outcomes of treatment with these monoclonal antibodies in humans to shed light on the mechanisms underlying the main immunological and hematological findings from these clinical trials in humans.
Keyphrases
- clinical trial
- induced apoptosis
- primary care
- signaling pathway
- type diabetes
- chronic obstructive pulmonary disease
- randomized controlled trial
- multidrug resistant
- metabolic syndrome
- drug delivery
- adipose tissue
- chronic rhinosinusitis
- insulin resistance
- cystic fibrosis
- cell proliferation
- zika virus
- cell death
- regulatory t cells
- cancer therapy
- binding protein
- skeletal muscle
- drug induced
- study protocol
- open label